title: Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients.
abstract: OBJECTIVE
  We reevaluated the serum p53 antibody (S-p53Ab) ELISA kit, which was approved as a tumor marker of colon cancer in the Japanese Health Insurance System in 2007.
  
  
  METHODS
  S-p53Ab was measured as a tumor marker in 154 colorectal cancer patients, and the results were categorized by clinical and pathological variables. We then compared the positive frequency of S-p53Ab, carcinoembryonic antigen (CEA), and carbohydrate 19-9 (CA19-9).
  
  
  RESULTS
  S-p53Ab was positive in 33.1% of the colorectal cancer patients. The positive rate was significantly higher in patients with lymph nodes metastasis (P = 0.025) and lymphatic invasion (P = 0.023). In patients with stage I colorectal cancer, the positive rate of S-p53Ab (23.7%) was significantly higher than that of CEA (5.3%) or CA19-9 (7.9%).
  
  
  CONCLUSIONS
  The approved kit for S-p53Ab testing was found to be an effective tumor marker of colorectal cancer. The positive rate of S-p53Ab was significantly higher in patients with cancer involvement of the lymphoid tissues. The positive rate of S-p53Ab was higher than that of CEA and CA19-9 in patients with stage I colorectal cancer, suggesting that the S-p53Ab is a useful tumor marker for patients with early-stage disease.
authors.affiliation: Department of Surgery, National Tokyo Medical Center, Tokyo, Japan. hochiai-jaem@a8.keio.jp
authors.forename: Hiroki
authors.initials: H
authors.lastname: Ochiai
authors.forename: Takashi
authors.initials: T
authors.lastname: Ohishi
authors.forename: Koji
authors.initials: K
authors.lastname: Osumi
authors.forename: Jo
authors.initials: J
authors.lastname: Tokuyama
authors.forename: Hidejirou
authors.initials: H
authors.lastname: Urakami
authors.forename: Shikou
authors.initials: S
authors.lastname: Seki
authors.forename: Atsushi
authors.initials: A
authors.lastname: Shimada
authors.forename: Akira
authors.initials: A
authors.lastname: Matsui
authors.forename: Yoh
authors.initials: Y
authors.lastname: Isobe
authors.forename: Yuya
authors.initials: Y
authors.lastname: Murata
authors.forename: Takashi
authors.initials: T
authors.lastname: Endo
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Ishii
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Hasegawa
authors.forename: Sumio
authors.initials: S
authors.lastname: Matsumoto
authors.forename: Yuko
authors.initials: Y
authors.lastname: Kitagawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000912:Antibodies, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood* / Q000276:immunology; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D015179:Colorectal Neoplasms / Q000097:blood* / Q000276:immunology / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012372:ROC Curve; D012189:Retrospective Studies; D016159:Tumor Suppressor Protein p53 / Q000097:blood / Q000276:immunology*; D055815:Young Adult
chemical_list: D000912:Antibodies, Neoplasm; D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D016159:Tumor Suppressor Protein p53
references.citation: Dig Dis Sci. 2000 Jan;45(1):122-8
references.pmid: 10695624
references.citation: Cancer. 2000 Oct 15;89(8):1677-83
references.pmid: 11042560
references.citation: Int J Cancer. 2000 Mar 15;85(6):791-5
references.pmid: 10709097
references.citation: J Surg Oncol. 1999 Jun;71(2):112-6
references.pmid: 10389868
references.citation: Science. 1994 Nov 4;266(5186):807-10
references.pmid: 7973635
references.citation: Cancer. 2003 Feb 1;97(3):682-9
references.pmid: 12548611
references.citation: Nature. 1989 Dec 7;342(6250):705-8
references.pmid: 2531845
references.citation: Am J Pathol. 1995 Sep;147(3):790-8
references.pmid: 7677190
references.citation: Int J Clin Oncol. 2001 Feb;6(1):45-9
references.pmid: 11706527
references.citation: Cancer Res. 1996 Nov 1;56(21):4917-21
references.pmid: 8895744
references.citation: Science. 1991 Jul 5;253(5015):49-53
references.pmid: 1905840
references.citation: Int J Cancer. 2001 Dec 15;94(6):859-63
references.pmid: 11745489
references.citation: Cancer. 1999 Jan 15;85(2):302-8
references.pmid: 10023696
references.citation: World J Surg. 2009 Feb;33(2):272-7
references.pmid: 19052812
references.citation: Int J Colorectal Dis. 2001 Feb;16(1):22-7
references.pmid: 11317693
references.citation: Int J Colorectal Dis. 2004 Mar;19(2):114-20
references.pmid: 14634775
references.citation: Eur J Surg. 2001 Jan;167(1):50-3
references.pmid: 11213822
references.citation: Int J Cancer. 1999 May 31;81(5):712-8
references.pmid: 10328221
references.citation: Ann Surg Oncol. 2009 Sep;16(9):2516-23
references.pmid: 19565285
references.citation: Br J Cancer. 1995 Sep;72(3):637-41
references.pmid: 7669574
references.citation: Surg Today. 2010 Mar;40(3):245-50
references.pmid: 20180078
references.citation: Lancet. 1990 Mar 24;335(8691):675-9
references.pmid: 1969059